Lantheus Holdings, Inc. (LNTH) Gross Margin
- Gross margin · 12 months: Value 60.14%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 60.14% | Gross profit / revenue. Period ending 2026-06-30. $936.02M ÷ $1.56B × 100 ≈ 60.14% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 936.02M USD | Gross Profit |
| Revenue | 1.56B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 620.29M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $936.02M | $1.56B | $620.29M | 60.14% |
| 2026-03-31 | $935.17M | $1.55B | $611.00M | 60.48% |
| 2025-12-31 | $941.95M | $1.54B | $599.66M | 61.10% |
| 2025-09-30 | $949.62M | $1.53B | $576.31M | 62.23% |
| 2025-06-30 | $969.38M | $1.52B | $551.27M | 63.75% |
| 2025-03-31 | $984.14M | $1.54B | $552.55M | 64.04% |
| 2024-12-31 | $988.29M | $1.53B | $545.62M | 64.43% |
| 2024-09-30 | $969.62M | $1.50B | $527.18M | 64.78% |
| 2024-06-30 | $927.44M | $1.44B | $510.57M | 64.49% |
| 2024-03-31 | $874.31M | $1.37B | $491.31M | 64.02% |
| 2023-12-31 | $709.54M | $1.30B | $586.89M | 54.73% |
| 2023-09-30 | $646.85M | $1.21B | $558.75M | 53.65% |
| 2023-06-30 | $594.33M | $1.12B | $530.62M | 52.83% |
| 2023-03-31 | $529.71M | $1.03B | $497.26M | 51.58% |
| 2022-12-31 | $581.70M | $935.06M | $353.36M | 62.21% |
| 2022-09-30 | $472.44M | $801.46M | $329.02M | 58.95% |
| 2022-06-30 | $367.68M | $664.24M | $296.56M | 55.35% |
| 2022-03-31 | $275.74M | $541.58M | $265.84M | 50.91% |
| 2021-12-31 | $187.69M | $425.21M | $237.51M | 44.14% |
| 2021-09-30 | $168.44M | $389.80M | $221.36M | 43.21% |
| 2021-06-30 | $162.03M | $376.27M | $214.24M | 43.06% |
| 2021-03-31 | $141.79M | $341.21M | $199.43M | 41.55% |
| 2020-12-31 | $138.76M | $339.41M | $200.65M | 40.88% |
| 2020-09-30 | $144.68M | $334.60M | $189.93M | 43.24% |
| 2020-06-30 | $150.00M | $331.84M | $181.83M | 45.20% |
| 2020-03-31 | $168.73M | $351.53M | $182.80M | 48.00% |
| 2019-12-31 | $174.81M | $347.34M | $172.53M | 50.33% |
| 2019-09-30 | $174.09M | $344.26M | (m) | 50.57% |
| 2019-06-30 | $177.39M | $347.39M | (m) | 51.06% |
| 2019-03-31 | $176.66M | $347.25M | (m) | 50.87% |
| 2018-12-31 | $174.88M | $343.37M | (m) | 50.93% |
| 2018-09-30 | $168.94M | $338.34M | (m) | 49.93% |
| 2018-06-30 | $162.58M | $329.38M | (m) | 49.36% |
| 2018-03-31 | $164.68M | $332.65M | (m) | 49.51% |
| 2017-12-31 | $162.13M | $331.38M | (m) | 48.93% |
| 2017-09-30 | $158.88M | $324.49M | (m) | 48.96% |
| 2017-06-30 | $154.04M | $317.61M | (m) | 48.50% |
| 2017-03-31 | $143.84M | $306.74M | (m) | 46.89% |
| 2016-12-31 | $137.78M | $301.85M | (m) | 45.64% |
| 2016-09-30 | $136.51M | $298.70M | (m) | 45.70% |
| 2016-06-30 | $136.54M | $299.76M | (m) | 45.55% |
| 2016-03-31 | $133.45M | $295.11M | (m) | 45.22% |
| 2015-12-31 | $135.52M | $293.46M | (m) | 46.18% |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | $131.23M | $303.09M | (m) | 43.30% |
| 2014-12-31 | $125.52M | $301.60M | (m) | 41.62% |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | $77.36M | $283.67M | (m) | 27.27% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |